These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31427271)

  • 1. The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy.
    Case BC; Bress AP; Kolm P; Philip S; Herrick JS; Granowitz CB; Toth PP; Fan W; Wong ND; Hull M; Weintraub WS
    J Clin Lipidol; 2019; 13(5):754-761. PubMed ID: 31427271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007-2014.
    Fan W; Philip S; Granowitz C; Toth PP; Wong ND
    Diabetes Care; 2019 Dec; 42(12):2307-2314. PubMed ID: 31575639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey.
    Fan W; Philip S; Granowitz C; Toth PP; Wong ND
    J Clin Lipidol; 2019; 13(1):100-108. PubMed ID: 30594443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey.
    Salami JA; Warraich H; Valero-Elizondo J; Spatz ES; Desai NR; Rana JS; Virani SS; Blankstein R; Khera A; Blaha MJ; Blumenthal RS; Lloyd-Jones D; Nasir K
    JAMA Cardiol; 2017 Jan; 2(1):56-65. PubMed ID: 27842171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients.
    Toth PP; Philip S; Hull M; Granowitz C
    Mayo Clin Proc; 2019 Sep; 94(9):1670-1680. PubMed ID: 31405751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study.
    Yang Q; Zhong Y; Gillespie C; Merritt R; Bowman B; George MG; Flanders WD
    BMJ Open; 2017 Jan; 7(1):e011684. PubMed ID: 28119384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States.
    Boettiger DC; Newall AT; Phillips A; Bendavid E; Law MG; Ryom L; Reiss P; Mocroft A; Bonnet F; Weber R; El-Sadr W; d'Arminio Monforte A; de Wit S; Pradier C; Hatleberg CI; Lundgren J; Sabin C; Kahn JG; Kazi DS
    J Int AIDS Soc; 2021 Mar; 24(3):e25690. PubMed ID: 33749164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
    Toth PP; Danese M; Villa G; Qian Y; Beaubrun A; Lira A; Jansen JP
    J Med Econ; 2017 Jun; 20(6):555-564. PubMed ID: 28097904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study.
    Schleyer T; Hui S; Wang J; Zhang Z; Knapp K; Baker J; Chase M; Boggs R; Simpson RJ
    J Manag Care Spec Pharm; 2019 May; 25(5):544-554. PubMed ID: 31039062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Mild-to-Moderate Hypertriglyceridemia.
    Pulipati VP; Brinton EA; Hatipoglu B
    Endocr Pract; 2022 Nov; 28(11):1187-1195. PubMed ID: 35850450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk.
    Toth PP; Granowitz C; Hull M; Liassou D; Anderson A; Philip S
    J Am Heart Assoc; 2018 Aug; 7(15):e008740. PubMed ID: 30371242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus.
    Nichols GA; Reynolds K; Olufade T; Kimes TM; O'Keeffe-Rosetti M; Sapp DS; Anzalone D; Fortmann SP
    Am J Cardiol; 2017 Feb; 119(3):410-415. PubMed ID: 27890243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated Impact of US Preventive Services Task Force Recommendations on Use and Cost of Statins for Cardiovascular Disease Prevention.
    Ngo-Metzger Q; Zuvekas SH; Bierman AS
    J Gen Intern Med; 2018 Aug; 33(8):1317-1323. PubMed ID: 29855861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol.
    Nichols GA; Philip S; Reynolds K; Granowitz CB; Fazio S
    Diabetes Obes Metab; 2019 Feb; 21(2):366-371. PubMed ID: 30225881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
    Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
    Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence.
    Toth PP; Fazio S; Wong ND; Hull M; Nichols GA
    Diabetes Obes Metab; 2020 Mar; 22(3):279-289. PubMed ID: 31742844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults.
    Kohli-Lynch CN; Bellows BK; Zhang Y; Spring B; Kazi DS; Pletcher MJ; Vittinghoff E; Allen NB; Moran AE
    J Am Coll Cardiol; 2021 Nov; 78(20):1954-1964. PubMed ID: 34763772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.